News from takeda pharmaceutical company limited A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 10, 2014, 09:00 ET

Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development

 Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during...

Jun 17, 2014, 09:00 ET

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

Takeda Pharmaceuticals Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced that the companies will present results about sexual...

Jun 16, 2014, 10:00 ET

ENTYVIO™ (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the...

Jun 16, 2014, 06:30 ET

New CONNECT Study Presents data on Measures of Cognitive Performance in Adult Patients Treated with Brintellix® (vortioxetine) for Major Depressive Disorder

 Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) today announced results from CONNECT, a new study that evaluated...

May 20, 2014, 18:14 ET

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the...

Mar 27, 2014, 08:00 ET

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...

Dec 24, 2013, 10:57 ET

Takeda Announces Extension of FDA PDUFA Action Date for Vedolizumab for Ulcerative Colitis

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that...

Dec 09, 2013, 20:09 ET

FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a...

Sep 30, 2013, 23:15 ET

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder

 Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) jointly announced today that the U.S. Food and Drug...

Sep 20, 2013, 09:00 ET

Takeda Cares Day Raises $63,700

 Takeda, a top 15 global pharmaceutical company, will raise money for local organizations today when employees participate in their third...

Sep 17, 2013, 14:38 ET

Takeda's Deerfield Campus Ranked Among 2013 Working Mother 100 Best Companies

Takeda Pharmaceuticals today announced Working Mother has listed Takeda among the top 100 companies for working mothers. Takeda's Deerfield campus...

Sep 12, 2013, 13:45 ET

Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR

 Takeda Pharmaceutical Company Limited (Takeda) and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC...

Sep 11, 2013, 14:06 ET

EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes

-- Im New England Journal of Medicine veröffentlichte und auf dem ESC Congress 2013 präsentierte klinische Daten Takeda...

Sep 04, 2013, 13:15 ET

Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that...

Sep 02, 2013, 02:00 ET
Aug 26, 2013, 11:40 ET
Aug 21, 2013, 17:00 ET

Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

 Takeda Pharmaceutical Company Limited ("Takeda") today announced that results from two Phase 3 studies evaluating vedolizumab, an...

Jul 17, 2013, 11:45 ET
Jun 21, 2013, 08:00 ET

Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a...